|
|
|
|
 |
 |
Hi ,
|
Don’t miss out on early bird pricing for conference pass tickets. Pricing goes up this Friday, March 1st. The nominations for the 2024 SynBioBeta awards are now open! Submit your nominations for individuals, companies, or organizations that deserve
recognition for their outstanding contributions to synthetic biology. The deadline is March 15. This year’s categories include Lifetime Achievement Award, Pioneer Award, Impact Award, Rising Star Award, and Industry Leader Award.
|
 |
Martine and Craig were winners of the 2023 SynBioBeta awards, and both are returning to speak again at SynBioBeta this year!
|
 |
This week’s digest is brought to you by Absci, a data-first generative AI drug creation company that combines AI and synthetic biology to create better biologics for patients faster. Absci was founded on the idea that E. coli could produce antibodies for pharma quicker and cheaper than traditional approaches.
|
 |
Sean McClain, CEO of Absci.
With advances in AI, E. coli became the hero of Absci’s story for a different reason: producing the training data needed to realize generative AI’s potential in biologic drug discovery. Absci just announced the start of IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody to help treat IBD, a disease affecting as many as 3 million patients in the US. It’s a big step forward for synthetic biology, AI, and drug discovery.
|
 |
Paul Stamets and Martine Rothblatt were fans of SynBioBeta last year - They loved the event so much that they are returning this year for a fireside chat together on Wednesday, May 8th, at 4:15 pm. This discussion will be a melding of mycology, biotechnology, and the philosophy of interconnectedness! I hope you can join us.
|
More Speakers Announced:
|
 |
New Sponsors & Exhibitors Coming to SynBioBeta 2024:
|
Hamilton Company specializes in developing, manufacturing, and customizing precision measurement devices, automated liquid handling workstations, and sample management systems.
GenScript is a leading biotech company focusing on early drug discovery and development services.
ZBiotics is the maker of the world's 1st engineered probiotic. Built to help you feel better the day after drinking alcohol by breaking down acetaldehyde.
seqWell delivers true multiplexing NGS library prep solutions for single cells to whole genomes without costly normalization or equipment.
On-Chip Biotechnologies’ mission is to assist researchers in accelerating the world’s discoveries in life science, drug development, and diagnostics with On-chip Sort.
Quantum Sky is a platform company that builds and integrates cutting-edge technologies to advance medicine, manufacturing, and AI.
Biomatter is a synthetic biology company that creates new proteins for health and sustainable manufacturing applications.
Mekonos is advancing a proprietary cell-engineering platform offering unprecedented precision in delivering multiplexed cargo into even the most fragile cells.
If you are interested in having a space on the floor, please contact our team here.
|
|
|
| Register now |
|
|
|
|
|
|
Industry News:
|
Engineering Against the Odds: A New Antibody's Battle with Leukemia. Scientists at City of Hope have developed a new therapy targeting hard-to-kill leukemia stem cells, offering hope for more effective treatment of acute myeloid leukemia.
Peptide-Powered Protein 'Lawnmower' Gets into the Weeds of Molecular Motors. SFU's 'Lawnmower' motor, which efficiently clears a path through peptide 'grass,' sheds light on nature's intricate machinery and reveals insights into biological locomotion, potentially revolutionizing medicine and
biocomputing.
OpenFold Biotech AI Research Consortium Unveils Groundbreaking Tools for Protein Research: These developments mark significant strides in protein research, offering faster and more precise protein structure predictions, improved models of protein interactions, and enhancements
in the design of therapeutic proteins.
Pivot Bio's N-OVATOR™ Program Pays Over $6 Million to Farmers for Sustainable Nitrogen Practices: N-OVATOR™, a pioneering insetting program targeting nitrous oxide emissions, offers prompt, yearly payments to farmers, marking a significant departure from traditional
agricultural compensation models.
Syngenta Crop Protection and Lavie Bio Forge Collaboration to Develop Biological Insecticidal Solutions: The collaboration aims to harness Lavie Bio's unique technology platform for the swift identification and optimization of bio-insecticide candidates, combined
with Syngenta’s extensive global research, development, and commercialization capabilities.
NIST Collaborates with EBRC to Enhance Safety in Nucleic Acid Synthesis Amid AI Advancements: This partnership seeks to develop screening and safety mechanisms to mitigate the potential risks associated with the misuse of artificial intelligence (AI) in nucleic acid
synthesis, an expanding domain within synthetic biology that holds considerable promise alongside significant risks.
Ansa Biotechnologies Names Jason T. Gammack as CEO Amid Advances in DNA Synthesis Technology: Ansa Biotechnologies, Inc., a leader in next-generation DNA synthesis, has appointed Jason T. Gammack as its new chief executive officer as the company advances its early access
program for complex synthetic genes and gene fragments, gearing up for a full commercial service launch. You can meet Ansa at SynBioBeta 2024.
‘Winging it’ in Gene Therapy with Avian Retrotransposons: Precise RNA-mediated INsertion of Transgenes (PRINT) utilizes a retrotransposon derived from these avian sources to seamlessly integrate genes into the human genome, offering a potential solution for a myriad of hereditary diseases.
|
Additional Industry News:
|
Regards,
John
---
John Cumbers
CEO, SynBioBeta
|
Who's hiring?
|
|
|
|
|
|
|
|
|
|
